FDA greenlights first blood test to diagnose Alzheimer’s disease

The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that could help in the diagnosis of Alzheimer’s disease.

Developed by Pennsylvania-based Fujirebio Diagnostics, Lumipulse G received the FDA’s 510 ((k)) clearance on Friday